Sagimet Biosciences (SGMT) Cash & Equivalents (2023 - 2024)
Sagimet Biosciences has reported Cash & Equivalents over the past 2 years, most recently at $77.0 million for Q3 2024.
- Quarterly results put Cash & Equivalents at $77.0 million for Q3 2024, down 24.38% from a year ago — trailing twelve months through Sep 2024 was $77.0 million (down 24.38% YoY), and the annual figure for FY2023 was $75.1 million, changed.
- Cash & Equivalents for Q3 2024 was $77.0 million at Sagimet Biosciences, down from $96.0 million in the prior quarter.
- Over the last five years, Cash & Equivalents for SGMT hit a ceiling of $176.8 million in Q1 2024 and a floor of $18.5 million in Q2 2023.